Leiden University
NGID | Next Generation Immunodermatology
More than 2.5 million Dutch people suffer from a chronic inflammatory disease of the skin. These diseases are often not life-threatening, but the personal consequences and social costs are very high. The biggest problem is that treatments often do not work sufficiently. To change this, we need to learn more about which treatment is best for which patient. That is why six skin diseases are investigated in great detail in this project. With this information, a patient-specific fingerprint of the disease will be created that will determine which treatment is best for each unique patient.
Applicant
- Leiden University
Consortium
- Leiden University Medical Centre
- University of Applied Sciences Leiden
- University of Amsterdam
- Maastricht University
- University Medical Centre Utrecht
- Technical University Delft
- Erasmus Medical Centre
- HAN University of Applied Sciences
- Radboud University Medical Centre
- University Medical Centre Groningen
- Centre for Human Drug Research (CHDR)
- Proefdiervrij
- River Diagnostics (RiverD)
- Janssen-Cilag B.V.
- Maruho (Japan)
- Almirall (Spain)
- Scibase (Sweden)
- CELLnTEC (Switzerland)
- Perimed AB (Sweden)
- Vereniging voor Mensen met Constitutioneel Eczeem (VMCE)
- Psoriasispatiënten Nederland
- Stichting Huidlymfoom
- Nederlandse Vereniging voor Dermatologie en Venereologie (NVDV)
- Nederlandse Vereniging voor Experimentele Dermatologie (NVED)
- Huid Nederland
- Clinical Microbiomics (Denemarken)
- FibroTx (Estonia)
- Damae Medical (France)
- ImaBiotech (France)
- Netherlands Enterprise Agency (RVO)
- Central Committee of Human Research (CCMO)
- Skin Research Institute of Singapore, Innovative Medicines Initiative
Grant
